TrialLancet (London, England)2021

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.

Alasdair P S Munro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.